Cancer Risks for PMS2-Associated Lynch Syndrome

Grants

Funding Acknowledgements

Supported by Grant No. UL-2012-5515 from the Dutch Cancer Society and Grant No. UM1 CA167551 from the National Cancer Institute and through cooperative agreements with the following Colon Cancer Family Registry centers: Australasian Colorectal Cancer Family Registry Grants No. U01 CA074778 and U01/U24 CA097735; Mayo Clinic Cooperative Family Registry for Colon Cancer Studies Grant No. U01/U24 CA074800; Ontario Familial Colorectal Cancer Registry Grant No. U01/U24 CA074783; Seattle Colorectal Cancer Family Registry Grant No. U01/U24 CA074794; University of Hawaii Colorectal Cancer Family Registry Grant No. U01/U24 CA074806; and University of Southern California Consortium Colorectal Cancer Family Registry Grant No. U01/U24 CA074799. Seattle Colon Cancer Family Registry research was also supported by the Cancer Surveillance System of the Fred Hutchinson Cancer Research Center, which was funded by Control Nos. N01-CN-67009 (1996 to 2003) and N01-PC-35142 (2003 to 2010) and Contract No. HHSN2612013000121 (2010 to 2017) from the SEER Program of the National Cancer Institute, with additional support from the Fred Hutchinson Cancer Research Center. The Columbus-area Hereditary Non-Polyposis Colorectal Cancer study cohort in Ohio was supported by Grants No. NCI R01-CA67941 and CA16058. The Ohio Colorectal Cancer Prevention Initiative was supported by Pelotonia. The collection of cancer incidence data for the State of Hawaii used in this study was supported by the Hawaii Department of Health as part of the statewide cancer reporting program mandated by Hawaii Revised Statutes; the National Cancer Institute's SEER under Control Nos. N01-PC-67001 (1996 to 2003) and N01-PC-35137 (2003 to 2010) and Contract Nos. HHSN26120100037C (2010 to 2013) and HHSN261201300009I (2010 to current) awarded to the University of Hawaii. The collection of cancer incidence data used in this study was supported by the California Department of Public Health as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the National Cancer Institute's SEER Program under Contract No. HHSN261201000140C awarded to the Cancer Prevention Institute of California, Contract No. HHSN261201000035C awarded to the University of Southern California, and Contract No. HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement No. U58DP003862-01 awarded to the California Department of Public Health. Data from Sweden were collected with support of the Swedish Cancer Society and the Stockholm County Council (ALF project). This work was also supported by the Spanish Ministry of Economy and Competitiveness, cofunded by European Regional Development Fund (FEDER) funds-a way to build Europe-Grant No. SAF2015-68016-R (G.C.); Carlos III National Health Institute (CIBERONC); the Government of Catalonia (Pla estrategic de recerca i innovacio en salut and 2014SGR338); and the Scientific Foundation Asociacion Espanola Contra el Cancer. A.K.W. is a National Health and Medical Research Council (NHMRC) Career Development Fellow. M.A.J. is an NHMRC Senior Research Fellow. J.L.H. is an NHMRC Senior Principal Research Fellow. D.D.B. is an NHMRC Career Development Fellow and a University of Melbourne Research at Melbourne Accelerator Program (R@MAP) Senior Research Fellow. C.R. is a Jeremy Jass Pathology Fellow. M.N. is a Dutch Cancer Society Fellow.